EMA Authorised: Jentadueto (linagliptin;metformin) — Boehringer Ingelheim International GmbH

View source ↗

Summary

European Medicines Agency authorizes Jentadueto (linagliptin/metformin) for type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Jentadueto (linagliptin/metformin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Boehringer Ingelheim International GmbH. Decision date: 05/06/2026